ClinicalTrials.gg
RecruitingNCT05642026Updated Oct 29, 2026

INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures

A Phase 4 interventional study of Ropivacaine and Non steroidal anti-inflammatory drug and opioids in Rib Fractures, sponsored by Zachary Warriner. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Zachary Warriner · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Rib Fractures with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Rib Fractures · United States.

Planned enrollment
3rd of 41
180 · median 36
Started
2025
with 4 others
Phase 4
17 of 48
3 open now
Registered
35th of 48
by date

Among the 48 studies in Rib Fractures with a site in United States, this one is the 3rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 4, and was the 35th registered.

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

Browse Rib Fractures studies →

Open to participants now

9 of the 48 studies in Rib Fractures with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rib Fractures studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Rib Fractures with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, randomized, non-blinded study comparing CINB plus medical therapy versus standard medical care (non-steroidals and opioids intravenous/oral inpatient and oral outpatient) alone for patients with multiple rib fractures. The objective of this study is to analyze the effect of continuous intercostal nerve block (CINB) in the treatment of patients admitted to the adult trauma service with rib fractures. The effectiveness of CINB as adjunctive treatment will be compared to standard medical therapy involving nonsteroidal and intravenous/oral opioid medications.

03

Conditions studied

  • Rib Fractures

Browse trials for

Keywords

  • intercostal
  • nerve block
  • opioid
  • non steroidal
  • inpatient
  • outpatient
  • catheter
  • anesthetic
  • epidural
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be at least 18 years old
  • Subjects will have 2 or more identified rib fractures
  • Subjects will be willing to provide for procedure
  • Subjects will be identified as appropriate for initiation of continuous nerve block therapy for treatment of rib fracture associated pain.

Exclusion criteria

Exclusion Criteria:

  • Documented allergy to study medication
  • Epidural catheter use
  • Prisoners
  • Refusal of CINB therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    continuous intercostal nerve block (CINB)

    patients admitted to the adult trauma service with rib fractures who are receiving CINB

    Drug: Ropivacaine · Drug: Non steroidal anti-inflammatory drug and opioids

  • Active comparator
    standard medical care

    patients admitted to the adult trauma service with rib fractures who are receiving standard medical care

    Drug: Non steroidal anti-inflammatory drug and opioids

Interventions

  • Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.

    Also known as: Naropin

  • DrugNon steroidal anti-inflammatory drug and opioids

    Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.

06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    time from randomization until the time of discharge

    Time frame: 7 days

Secondary outcomes

  1. Patient daily pain scores

    Pain will be assessed using a 10-Point Numerical Pain Scale (as part of standard of care) every day while patient is hospitalized and 2 days following discharge at follow contact. Scores range from 0-10; higher scores indicated higher levels of pain.

    Time frame: 7 days

  2. Modified Morphine Equivalent (MME) differences

    Total morphine milligram equivalents (MME) will be assessed

    Time frame: 7 days

  3. hospital-free days

    number of outpatient days for 1 month following randomization

    Time frame: 30 days

  4. spirometry values

    measurements of inspiratory volume in milliliters will be taken pre-placement, 60 minutes after catheter insertion, the following day, and each subsequent morning

    Time frame: 7 days

  5. mean respiratory rates

    number of inspiratory cycles per minute taken each day until the patient is discharged

    Time frame: 7 days

  6. Patient reported quality of life

    Patient reported quality of life will be measured through the EuroQol instrument (EQ-5D-5L). The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems."

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 8, 2022
StartActual
Sep 23, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05642026
Lead sponsor
Zachary Warriner
Responsible party
Zachary Warriner (Assistant Professor, University of Kentucky) — Sponsor-investigator
First posted
Dec 8, 2022
Start date
Sep 23, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Zachary Warriner, MD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion